9 Publikationen
-
2024 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2987695Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapyPUB | DOI | PubMed | Europe PMC
Krug, David, Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast 74 (). , 2024 -
2024 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2987540Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancerPUB | WoS
Herold, Natalie, Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer. Abstracts from the 56th European Society of Human Genetics (ESHG) Conference 32 (Suppl. 1). London, 2024 -
2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2979534Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma PatientsPUB | PDF | DOI | WoS | PubMed | Europe PMC
Imterat, Majdi, Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients. Cancers 15 (9). , 2023 -
2023 | Kurzbeitrag Konferenz / Poster | Veröffentlicht | PUB-ID: 2985382PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trialPUB | DOI | WoS
Slomovitz, B. M., PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial. Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023 34 (Suppl. 2). Amsterdam, 2023 -
2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2984317Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological imagesPUB | DOI | WoS | PubMed | Europe PMC
Marme, Frederik, Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images. European Journal of Cancer 195 (). , 2023 -
2023 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 2984002Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal studyPUB | DOI | WoS | PubMed | Europe PMC
Imterat, Majdi, Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study. Gynecologic Oncology 178 (). , 2023 -
2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2984318Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?PUB | DOI | WoS | PubMed | Europe PMC
Bizzarri, Nicolo, Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?. European Journal of Cancer 195 (). , 2023 -
2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2980959Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancerPUB | DOI | WoS | PubMed | Europe PMC
Herold, Natalie, Pathogenic germline variants in SMARCA4 and further cancer predisposition genes in early onset ovarian cancer. Cancer Medicine (). , 2023 -
2023 | Zeitschriftenaufsatz | E-Veröff. vor dem Druck | PUB-ID: 2979540The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial designPUB | DOI | WoS | PubMed | Europe PMC
Inci, Melisa Guelhan, The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design. International Journal of Gynecological Cancer (). , 2023